BGMS — Bio Green Med Solution Share News
0.000.00%
Last trade - 00:00- $6.36m
- $2.57m
- $0.75m
Brief: Cyclacel Pharmaceuticals Got Notice From European Patent Office Of Intention To Grant Patent Covering Plogosertib Pharmaceutical Compositions
Brief: Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Cyclacel Pharmaceuticals Inc expected to post a loss of $4.74 a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of $4.74 a share - Earnings Preview
Brief: Cyclacel Pharmaceuticals Inc Files For Resale Of Up To 15.2 Million Shares By The Selling Stockholders
Brief: Cyclacel Pharmaceuticals Says Board Passed A Resolution To Suspend Payment Of quarterly dividend On Preferred Stock Scheduled For May 1, 2024
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Cyclacel Pharmaceuticals Inc expected to post a loss of $5.89 a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of $5.89 a share - Earnings Preview
Brief: Cyclacel Pharmaceuticals Announces Reverse Stock Split
Brief: Cyclacel Receives Notification Of Deficiency From Nasdaq Regarding Timely Filing Of Quarterly Report
Brief: Cyclacel Q3 Net Income USD -6.097 Million
Cyclacel Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Cyclacel Q2 basic EPS USD -0.44
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Cyclacel Pharmaceuticals Inc expected to post a loss of 50 cents a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Cyclacel Pharma Got Letter Notifying That Nasdaq Has Granted Co Until Jan 2, 2024 To Regain Compliance With Minimum Bid Price Rule